Group B Streptococcus (GBS) Market Poised for 11.2% CAGR by 2033| Diagnostic Kits Lead with 60% Share, North America Holds 40% Revenue| DataM Intelligence

Leander, Texas-The global Group B Streptococcus (GBS) vaccines market was valued at $158 million in 2024. It is projected to experience robust growth with a compound annual growth rate (CAGR) of 11.2% from 2025 to 2033. The primary driver for this growth is the increasing focus on maternal and neonatal health.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/group-b-streptococcus-market?pratik

🔹 United states industry development:-
✔ U.S. dominates North America's GBS infection treatment market with advanced prenatal care and high healthcare spending.

✔ GBS diagnosis market valued at USD 1.67 billion in 2025, expected to grow to USD 2.45 billion by 2032 at 5.6% CAGR.

✔ Strong adoption of molecular diagnostics and AI in GBS screening enhances accuracy and reduces turnaround times.

✔ Increasing focus on maternal and neonatal health drives routine GBS screening adoption.

✔ Leading companies include Pfizer Inc., Novartis AG, Merck & Co., Inc., and GlaxoSmithKline plc.

🔹 Japan industry development

✔ Japan is a key Asia-Pacific market with matured regulatory frameworks and consistent investment inflows.

✔ Emphasis on AI and molecular diagnostics to improve GBS detection accuracy and speed.

✔ Market growth is influenced by government updates to regulatory guidelines and reimbursement policies favoring molecular diagnostics.

✔ Aging population and increasing focus on personalized and digital healthcare influence market trends.

✔ Japan's GBS nucleic acid detection kit market shows growth driven by technological advancements, healthcare digitalization, and regional supply chain integration with South Korea, China, and ASEAN.

🔹 Market segmentation-

✔ By Product:

Diagnostic kits dominate with approximately 60% of the market share, driven by nucleic acid-based detection technologies.

Therapeutics, including antibiotics and vaccines, hold about 30%, with vaccine development gaining traction.

Screening and monitoring consumables make up around 10%, reflecting routine testing in prenatal care.

✔ By Application (Global Market Share):

Prenatal screening and diagnostics: 55%, primary application due to prevention of neonatal infections.

Treatment of GBS infections in neonates and adults: 30%, addressing acute infection cases.

Research and development in GBS vaccine and therapeutics: 10%, focusing on innovation and preventive solutions.

Other uses, including veterinary and industrial microbiology: 5%.

✔ By End-User:

Hospitals and maternity clinics represent 70% of end-users, being primary points for prenatal screening.

Diagnostic laboratories hold 20%, supporting testing services and confirmations.

Research institutions and pharmaceutical companies constitute 10%, driving clinical trials and vaccine research.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=group-b-streptococcus-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

🔹 Regional insights-

➠ North America:

This is the largest market segment for the GBS ecosystem. For instance, in the GBS vaccine market, North America accounted for 39% of global share in 2024.

The leading position is driven by advanced healthcare infrastructure, strong R&D in maternal/neonatal immunization, and proactive government policies.

In diagnostics (nucleic acid detection kits), North America also holds the highest share (35 %) in recent reports.

For GBS infection treatment, the region contributed around 40% of total revenue in 2023.

➠ Asia‐Pacific:

This region is typically the fastest-growing in the GBS space. In the vaccine market, Asia‐Pacific is projected to grow at a very high CAGR (some reports estimate 14.2%) over the forecast horizon.

Key growth drivers include rising healthcare investments, increasing awareness of maternal/neonatal health, and improving infrastructure in populous countries like China, India, and Japan.

➠ Europe:

A mature but steadily growing market. For instance, in the GBS vaccine space, Europe had a significant share (USD 320 million in 2024) and is projected to grow moderately.

Growth is underpinned by well-established prenatal screening programs, strong public health frameworks, and collaboration between regulatory bodies and vaccine/diagnostic manufacturers.

🔹 Emerging players in the geopolymer market :-

✔ Novartis AG ( 10% market share): Expanding portfolio in GBS antibiotics and therapies; strong global presence and R&D.

✔ Pfizer Inc. ( 20% market share): Market leader with wide product range including diagnostics, vaccines, and treatments; strong pipeline and investments.

✔ GlaxoSmithKline plc ( 12% market share): Emphasizes vaccine research and maternal screening solutions; well-established market footprint.

✔ Alopexx Pharmaceuticals, LLC ( 5% market share): Strong in GBS vaccine development; progressing well in clinical trials for novel immunotherapies.

✔ Wellstat Vaccines LLC ( 4% market share): Advancing Phase 3 vaccine clinical trials; known for innovative vaccine tech improving neonatal protection.

✔ Minervax ApS ( 3% market share): Focuses on therapeutic vaccines and diagnostic improvements; gaining attention for targeted GBS treatment.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/group-b-streptococcus-market?pratik

🔹 Key Investment:

➠ Pfizer Inc. : Invested over USD 150 million in expanding GBS vaccine pipeline and acquisitions like Alopexx Pharmaceuticals.

➠ Wellstat Vaccines LLC: Raised USD 75 million for Phase 3 clinical trials on GBS vaccines, focusing on neonatal protection.

➠ Minervax ApS: Secured USD 40 million in funding for monoclonal antibody treatments targeting GBS infections.

➠ Novartis AG: Invested USD 100 million in antibiotic and therapeutic development for GBS, aiming to strengthen global presence.

➠ GlaxoSmithKline plc: Allocated USD 60 million towards maternal GBS vaccine research and diagnostic technologies.

🔹 Growth Drivers:-

Rising global incidence of GBS infections, especially in newborns and pregnant women, increases demand for effective diagnosis and treatment.

Growing awareness among healthcare professionals and expectant mothers about serious health risks like sepsis and meningitis.

Advancements in rapid and accurate molecular diagnostic technologies improving early GBS detection.

Increasing R&D investments by pharmaceutical companies for novel therapeutics and preventive vaccines.

Government initiatives promoting maternal and neonatal health and screening programs worldwide.

Expanding healthcare infrastructure and rising healthcare expenditure, particularly in North America, Europe, and Asia-Pacific.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.